More topics

Limited coverage criteria – finerenone

Last updated on March 26, 2025

 

Return to Special Authority drug list

Generic name

finerenone

Strength & form

10 mg/20 mg tablet

Special Authority criteria

Approval period

As an adjunct to standard care therapy1 to reduce the risk of end-stage kidney disease and a sustained decrease in estimated glomerular filtration rate (eGFR), and cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D) who:

Are receiving maximally tolerated doses of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)

AND

Are receiving maximally tolerated doses of a sodium-glucose cotransporter-2 inhibitor (SGLT2i)

AND

Have an eGFR of at least 25 mL/min/1.73 m2

AND

Have an albuminuria level of at least 3 mg/mmol (or 30 mg/g)

AND

Do not have chronic heart failure (CHF) New York Heart Association (NYHA) class II-IV

AND

Are not on concurrent treatment with a different Mineralocorticoid Receptor Antagonist (MRA)

AND

​When treatment is prescribed by a prescriber with experience in the diagnosis and management of patients with CKD and T2D, or in consultation with a nephrologist

Indefinite

Practitioner exemptions

  • None

Special notes

  • 1Standard of Care therapies in patients with CKD and T2D who have persistent albuminuria, is defined as maximally tolerated doses of an ACEi or ARB, in combination with an SGLT2i, unless SGLT2i are contraindicated or not tolerated
  • 2Coverage will not be provided for two 10 mg tablets to achieve a 20 mg daily dose because the cost is approximately double the cost of a single 20 mg tablet

Special Authority request form(s)